No Data
Could The Market Be Wrong About CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Given Its Attractive Financial Prospects?
CSPC Innovation Pharmaceutical (300765.SZ) subsidiary Giant Stone Biotech SYS6010 drug has been included in the list of breakthrough therapy products.
CSPC Innovation Pharmaceutical (stock code 300765.SZ) announced that its subsidiary CSPC Pharma's Jusheng Bio-Pharmaceutical Co., Ltd. (referred to as ...
CSPC Innovation Pharmaceutical Among 3 Stocks That May Be Priced Below Estimated Value
CSPC Innovation Pharmaceutical (300765.SZ): The antibody-drug conjugate SYS6043 from Giant Stone Bio has been approved for clinical trials.
On December 20, Glorun announced that CSPC Innovation Pharmaceutical (300765.SZ) disclosed that its subsidiary CSPC PHARMA Giant Stone Biological Pharmaceutical Co., Ltd. (referred to as "Giant Stone Biological") recently received the approval from the National Medical Products Administration for the "Clinical Trial Approval Notice" concerning SYS6043, which will soon commence clinical trials. SYS6043 is a monoclonal antibody-drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins to kill tumor cells. SYS6043 is classified as a Class 1 Biological Product for therapeutic use.
Those Who Invested in CSPC Innovation Pharmaceutical (SZSE:300765) Five Years Ago Are up 406%
CSPC Innovation Pharmaceutical Get US FDA Fast Track Qualification for Cervical Cancer Drug
No Data
